HBeAg positive (study 026): treatment with entecavir for up to 96 weeks (n = 141) resulted in cumulative response rates of 30% for HBV DNA < 300 copies/ ml by PCR, 85% for ALT normalisation and 17% for HBeAg seroconversion.